Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Professor Sir Marc Feldmann AC FAA FRS FRCP FRCPATH FMEDSC is a preeminent immunologist at the Kennedy Institute, University of Oxford. Feldmann has worked on immunology since the 1970s, and whilst working at the Imperial Cancer Research Fund’s Tumour Immunology Unit with Professor Avrion Mitchison he developed a new hypothesis in 1983 for the mechanisms behind autoimmunity, highlighting the role of cytokines.
His team discovered the importance of TNF in rheumatoid arthritis and subsequently developed anti-TNF therapy. Professor Feldmann’s patent was marketed by Centocor as Remicade, which was the key driver behind Johnson & Johnson’s $4.9 Billion USD acquisition of Centocor in 1999.
Anti-TNF therapeutics currently lead the global drugs market, and Remicade alone had over $7.7 Billion USD of sales in 2017 – making it Johnson & Johnson’s best-selling drug.
Professor Sir Marc Feldmann has received numerous recognitions for his important discoveries. He is a fellow of, among others, the Royal College of Physicians, the Royal College of Pathologists, the Royal Society and the Australian Academy of Science. In 2010 he was knighted in the Queen’s Birthday Honours for services to medicine.
Among the prizes awarded to Feldmann and his colleagues are the Crafoord Prize, the Albert Lasker Award (2003), the Cameron Prize for Therapeutics (2004), the John Curtin Medal (2007), the Dr Paul Janssen Award for Biomedical Research (2008), the Ernst Schering Prize (2010), and the Canada Gairdner International Award (2014).
Professor Sir Marc Feldmann has authored over 600 published papers reflecting his overarching interests in the cellular aspects of inflammatory autoimmune biology messenger molecules, cytokines, and therapeutic applications.
Possessing decades of experience in orthopaedic treatment, Glenn Copeland is one of Canada’s most prominent podiatrists. He has been working on CBD-based formulations to combat inflammation for the last three and a half years.
Dr Copeland has founded and directed several highly successful medical companies. Among them are FootMaxx Inc, which converted orthopaedic evaluation of the lower extremity from moulding technology to pressure and motion mapping and was successful in opening 1,880 clinics around the world.
Glenn has long and varied experience in top medical institutions. Between 2002 and 2008, he was the founder, chairman, and CEO of Cleveland Clinic Canada. Cleveland Clinic is regarded as one of the top three medical institutions in the world.
He was recruited in 2008 by Mount Sinai Hospital in Toronto to establish the Rehab and Wellbeing Center which continues to thrive, seeing over 10,000 patients each year.
As an expert in the treatment of sports injuries, Dr Copeland has offered invaluable advice and service since 1979 in his role as the team podiatrist of the Major League Baseball team the Toronto Blue Jays. He is also the Medical Director of the Ottawa Sports and Entertainment Group, which re-established Canadian Football in the city and culminated in the Ottawa Red blacks’ triumph in the 2016 Grey Cup. Glenn Copeland is also a well-respected and popular author. He has written five international books and is especially well-known for his works ‘The Foot Doctor’ and ‘Healthy Feet’, which have been translated into twelve languages.
Marcy possesses in-depth knowledge of sports medicine. She is a graduate of Northeastern University, where she received a BSc in Athletic Training. She continued her academic career earning a MSc in Applied Anatomy and Physiology from Boston University.
Whilst studying, Marcy gained significant experience relating to the sports medicine market by working with, among others, Harvard University’s football team, Northeastern University’s men’s ice hockey team, and Washington Northeastern University’s women’s basketball, soccer, and track and field squads.
She has been involved in the business side of healthcare for the past 6 years; Marcy was the Director of Business Development and Operations, and a board member, of Performance Orthotics.
Marcy has worked with Dr Glenn Copeland at his clinic in the Mount Sinai Hospital in Toronto since 2010, where her identification and improvement of issues has led to marked increases in patient satisfaction, as well as significant profitable growth.
She is a native of Connecticut and is a member of the National Athletic Trainers’ Association, as well as being a licensed athletic trainer by the Massachusetts Board of Allied Health.
Dave Wright is a highly-qualified, professional and athletic therapist and brings this experience to Copeland Biosciences. He has been practicing as a Certified Athletic Therapist for over 30 years and is an active member of both the Canadian Athletic Therapists Association and the Ontario Athletic Therapist Association.
Prior to his time with Copeland Biosciences, Dave was a staff member of the University of Guelph Athletics Department working with varsity teams and athletes.
In professional sports, Dave held the position Director of Athletic Therapy for Ottawa Sports and Entertainment Group managing the sports medicine and conditioning departments for the 2016 Canadian Football League Grey Cup Champion Ottawa Redblacks, the Ottawa Fury FC soccer team and the Ottawa 67’s hockey club.
He was also the Head Athletic Therapist for the 100th CFL Grey Cup Champions Toronto Argonauts Football Club. Dave has served as a member of the CFL Medical Committee and as a board member of the CFL Health and Safety Committee.
Aaron Copeland began as a high-achieving undergraduate at Dalhousie University, where, in his second year, he was accepted into an internationally renowned law program at Monash University where he obtained his BA and LL.B.
During his studies, Aaron gained experience in the sports industry interning for the Toronto Blue Jays Baseball Operations Department. After obtaining his degree in law, Aaron was called to the Ontario Bar.
He began his career in business development with a prominent legal software company, where he cultivated a large client base consisting of some of Ontario’s most respected legal practices. Aaron brings this business experience as well as his incisive mind to Copeland Biosciences.
Aaron will join Copeland Biosciences as the in-house legal consultant, where he will also work closely with the sales team in order to exploit potential opportunities in the marketplace.
Julie Guerrero is a kinesiologist who partners with a collection of orthopaedic surgeons and sports medicine specialists providing medical orthoses and state-of-the-art therapeutic modalities to an all-age population.
She is an active member of both the Ontario Kinesiology Association and College of Kinesiologists of Ontario.
Julie holds a BA in Kinesiology from York University, Toronto, Ontario. Although her studies and experience laid the groundwork for her exciting career, Julie’s core strengths are connecting and communicating with the people she meets on a daily basis. Julie excels in a community setting with a strong emphasis on building relationships.
Julie’s passion stands in project management. In keeping with the rapid technological advances in the modern world, Julie currently is managing a 3D solution to creating prefabricated orthoses.
Julie’s dynamic roles and experience will be a great asset to Copeland Biosciences.
Professor Nunchahal is a surgeon scientist and the Professor of Hand, Plastic & Reconstructive Surgery at the University of Oxford.
His PhD, undertaken in London, was funded by the Medical Research Council and whilst studying Professor Nunchahal led a lab group funded by external grants throughout his surgical training.
Before settling at Oxford, Professor Nunchahal held fellowships at Imperial College London and the University of Sydney in his specialist area of plastic surgery. Professor Nunchahal is based at the University of Oxford’s Kennedy Institute of Rheumatology, with which he became associated through his work with patients suffering from rheumatoid arthritis.
His most recent research explores tissue regeneration by the targeting of endogenous stem cells, and by reducing fibrosis. In 2013, Professor Nunchahal’s group identified TNF as a therapeutic target for Dupuytren’s disease, a common fibrotic condition of the hand.
He is currently leading a phase 2b trial funded by the Wellcome Trust and the Department of Health to investigate treatment of this condition.
Professor Nunchahal also possesses experience in business administration in the health industry; between 2008 and 2011 he was Chief of Muskoskeletal Services, specializing in orthopaedics and rheumatology, and in the same period completed a mini-MBA in healthcare management at Imperial College, London.
There have been numerous recognitions of Professor Nunchahal’s important contributions to science and surgery, and he has been made a member of the Royal College of Surgeons and the Royal Australasian College of Surgeons.